E-Book Overview
The first edition of Comprehensive Medicinal Chemistry was published in 1990 and was very well received. Comprehensive Medicinal Chemistry II is much more than a simple updating of the contents of the first edition. Completely revised and expanded, this new edition has been refocused to reflect the significant developments and changes over the past decade in genomics, proteomics, bioinformatics, combinatorial chemistry, high-throughput screening and pharmacology, and more. The content comprises the most up-to-date, authoritative and comprehensive reference text on contemporary medicinal chemistry and drug research, covering major therapeutic classes and targets, research strategy and organisation, high-throughput technologies, computer-assisted design, ADME and selected case histories. It is this coverage of the strategy, technologies, principles and applications of medicinal chemistry in a single work that will make Comprehensive Medicinal Chemistry II a unique work of reference and a single point of entry to the literature for pharmaceutical and biotechnology scientists of all disciplines and for many industry executives as well.Also available online via ScienceDirect (2006) - featuring extensive browsing, searching, and internal cross-referencing between articles in the work, plus dynamic linking to journal articles and abstract databases, making navigation flexible and easy. For more information, pricing options and availability visit www.info.sciencedirect.com. * Comprehensively reviews - the strategies, technologies, principles and applications of modern medicinal chemistry * Provides a global and current perspective of today's drug discovery process and discusses the major therapeutic classes and targets* Includes a unique collection of case studies and personal assays reviewing the discovery and development of key drugs
E-Book Content
Comprehensive Medicinal Chemistry II Volume 2 : Strategy and Drug Research Elsevier, 2006 Editors-in-Chief: John B. Taylor and David J. Triggle ISBN: 0-08-044513-6
Introduction 2.01 The Intersection of Strategy and Drug Research, Pages 1-84, W.H. Moos 2.02 An Academic Perspective, Pages 85-97, D.J. Triggle 2.03 An Industry Perspective, Pages 99-135, W. Wierenga Organizational Aspects and Strategies for Drug Discovery and Development 2.04 Project Management, Pages 137-158, Y. Nakagawa and L. Lehman 2.05 The Role of the Chemical Development, Quality, and Regulatory Affairs Teams in Turning a Potent Agent into a Registered Product, Pages 159-172, S.A. Munk 2.06 Drug Development, Pages 173-202, P. Preziosi 2.07 In-House or Out-Source, Pages 203-223, R.D. Connell 2.08 Pharma versus Biotech: Contracts, Collaborations, and Licensing, Pages 225-238, D. Cavalla 2.09 Managing Scientists, Leadership Strategies in Science, Pages 239-252, A.M. Sapienza 2.10 Innovation (Fighting against the Current), Pages 253-264, R. Root-Bernstein 2.11 Enabling Technologies in Drug Discovery: The Technical and Cultural Integration of the New with the Old, Pages 265-287, M. Williams 2.12 How and Why to Apply the Latest Technology , Pages 289-557, A.W.
Czarnik and H-Y Mei 2.13 How and When to Apply Absorption, Distribution, Metabolism, Excretion, and Toxicity, Pages 559-572, R.J. Zimmerman 2.14 Peptide and Protein Drugs: Issues and Solutions, Pages 573-601, J.J. Nestor 2.15 Peptidomimetic and Nonpeptide Drug Discovery: Receptor, Protease, and Signal Transduction Therapeutic Targets, Pages 603-647, T.K. Sawyer 2.16 Bioisosterism, Pages 649-711, C.G. Wermuth, P. Ciapetti, B. Giethlen and P. Bazzini 2.17 Chiral Drug Discovery and Development – From Concept Stage to Market Launch, Pages 713-736, H.-J. Federsel 2.18 Promiscuous Ligands, Pages 737-752, S.L. McGovern Targets 2.19 Diversity versus Focus in Choosing Targets and Therapeutic Areas, Pages 753-770, D.A. Giegel, A.J. Lewis and P. Worland 2.20 G Protein